Answers are grounded in this paper and cite their sources.
Background: The human papillomavirus (HPV) is the cause of warts, which are benign epithelial proliferations. Traditional therapies, such as salicylic acid and cryotherapy, frequently have poor results and a high rate of recurrence. A viable substitute is intralesional immunotherapy using the MMR vaccine, which boosts the host immune system to eradicate HPV-infected cells. The purpose of this study was to assess the intralesional MMR vaccine's effectiveness and safety in treating warts. Methods: Fifty-two patients with warts participated in a randomized clinical trial. Five intralesional MMR vaccination sessions were given to the participants at two-week intervals. At baseline and following five sessions, wart size and resolution were measured. Throughout the course of the study, adverse effects were observed. Results: After five sessions, 73.1% of patients had completely cleared their warts. There were no notable systemic side effects, and the most frequently reported adverse effect was mild erythema at the injection site. Conclusions: The intralesional MMR vaccine is a safe and efficient way to treat warts. It is less expensive than traditional treatments and has a lower chance of recurrence. To verify its long-term effectiveness, more research with bigger sample sizes and longer follow-up times is required.
No takes yet. Share an insight, caveat, or question.
Venkataramanappa et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: